Conducting a clinical trial during the pandemic? Here’s what you need to know from the FDA’s updated guidance.

The US FDA today issued updated guidance to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the COVID-19 public health emergency.

The guide goes further within an appendix explaining general considerations by providing answers to questions that the Agency has received about conducting clinical trials during the COVID-19 pandemic.

Available to download directly from the FDA here: the guidance is non-binding and provides recommendations rather than law, with the objective of ensuring the continued safety of trial participants. Sponsors are encouraged to consider each circumstance, focusing on the potential impact on the safety of trial participants, and modify each study conduct accordingly.

It’s clear that choosing a pharma partner who is alert, aware, professional, and fluid enough to adjust to the unpredictable daily developments is paramount. Contact us today to discuss your clinical testing needs or to find out more.

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency